The case involved a 44-year-old man who underwent intersphincteric resection and lateral
lymph node dissection for
rectal cancer. Pathological diagnosis revealed a well-differentiated
adenocarcinoma comprising KRAS wild type, and pT2N0M0 (pathological Stage I). CapeOX (
capecitabine plus
oxaliplatin[L-OHP]), and
bevacizumab therapy was initiated because of local recurrence. Although a partial response (PR) was observed, the
therapy was terminated after 6 courses because of the development of
hand-foot syndrome. FOLFIRI and
cetuximab therapy was initiated after
cancer recurrence was observed during a follow up. As the therapeutic efficiency is characterized by stability (stable disease: SD), and the
tumor reduction effect observed was not sufficient, we performed an
abdominoperineal resection to achieve local control. However, a left
hydronephrosis occurred due to the pelvic recurrence, necessitating the emergency hospitalization of the patient. Because resistance to L-OHP was not confirmed, mFOLFOX6 and
bevacizumab therapy was introduced in hopes of the effect of the former. As Grade 2
allergy (
erythema) appeared immediately after the L-OHP was administered during the 3 courses, treatment was discontinued. We the reinitiated the treatment along with the desensitization
therapy from the 4 courses. A total of 27 courses of mFOLFOX6 and
bevacizumab therapy were administered until the state of
disease progression (
progression disease: PD) was determined. PR was defined as the best therapeutic efficiency. In some cases, discontinuation of treatment is necessary as observed in the present case due to the onset of L-OHP
allergies, even if the overall effect of the treatment is expected to be good. Our case is essentialas it demonstrates the successfulness of desensitization
therapy for L-OHP
allergies.